Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinghong Han

Showing results (71-80 of 143) with videos related to

Pageof 15
Sort By:
Anticancer Research|August 28, 2024
[<sup>11</sup>C]Methionine PET <i>vs</i>. [<sup>18</sup>F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in PatientsMotokazu Sato, Toshihiko Sato, Chihiro Hozumi, et al.
Anticancer Research|August 28, 2024
First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker DecreaseMotokazu Sato, Qinghong Han, Chihiro Hozumi, et al.
In Vivo (Athens, Greece)|October 29, 2022
Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse ModelNoriyuki Masaki, Qinghong Han, Nathaniel F Wu, et al.
Anticancer Research|October 26, 2022
Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse ModelNoriyuki Masaki, Qinghong Han, Carissa Samonte, et al.
Biochemical and Biophysical Research Communications|August 19, 2019
Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse modelJun Ho Park, Ming Zhao, Qinghong Han, et al.
Anticancer Research|December 30, 2025
Methionine Restriction, Not Cysteine Restriction, Is a Cancer-specific VulnerabilityYuta Miyashi, Kohei Mizuta, Yohei Asano, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer TreatmentYutaro Kubota, Qinghong Han, Yusuke Aoki, et al.
Anticancer Research|March 27, 2026
The Glucose and Glutamine Requirements of Cancer and Normal Cells Do Not Distinguish Them, in Contrast to Their Methionine Requirement, Suggesting the Warburg Effect Is Not a Cancer ParadigmYuta Miyashi, Kohei Mizuta, Tomoyuki Ishiguro, et al.
Pancreas|December 28, 2020
Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft ModelNorihiko Sugisawa, Jun Yamamoto, Qinghong Han, et al.
Anticancer Research|January 30, 2026
Glutamine Dependence Is Not a Cancer-specific Vulnerability in Contrast to Methionine DependenceYuta Miyashi, Kohei Mizuta, Yohei Asano, et al.
Pageof 15

Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
Anticancer Research|August 28, 2024
[<sup>11</sup>C]Methionine PET <i>vs</i>. [<sup>18</sup>F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in PatientsMotokazu Sato, Toshihiko Sato, Chihiro Hozumi, et al.
Anticancer Research|August 28, 2024
First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker DecreaseMotokazu Sato, Qinghong Han, Chihiro Hozumi, et al.
In Vivo (Athens, Greece)|October 29, 2022
Oral-recombinant Methioninase Lowers the Effective Dose and Eliminates Toxicity of Cisplatinum for Primary Osteosarcoma of the Mammary Gland in a Patient-derived Orthotopic Xenograft Mouse ModelNoriyuki Masaki, Qinghong Han, Nathaniel F Wu, et al.
Anticancer Research|October 26, 2022
Oral-recombinant Methioninase in Combination With Rapamycin Eradicates Osteosarcoma of the Breast in a Patient-derived Orthotopic Xenograft Mouse ModelNoriyuki Masaki, Qinghong Han, Carissa Samonte, et al.
Biochemical and Biophysical Research Communications|August 19, 2019
Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse modelJun Ho Park, Ming Zhao, Qinghong Han, et al.
Anticancer Research|December 30, 2025
Methionine Restriction, Not Cysteine Restriction, Is a Cancer-specific VulnerabilityYuta Miyashi, Kohei Mizuta, Yohei Asano, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer TreatmentYutaro Kubota, Qinghong Han, Yusuke Aoki, et al.
Anticancer Research|March 27, 2026
The Glucose and Glutamine Requirements of Cancer and Normal Cells Do Not Distinguish Them, in Contrast to Their Methionine Requirement, Suggesting the Warburg Effect Is Not a Cancer ParadigmYuta Miyashi, Kohei Mizuta, Tomoyuki Ishiguro, et al.
Pancreas|December 28, 2020
Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft ModelNorihiko Sugisawa, Jun Yamamoto, Qinghong Han, et al.
Anticancer Research|January 30, 2026
Glutamine Dependence Is Not a Cancer-specific Vulnerability in Contrast to Methionine DependenceYuta Miyashi, Kohei Mizuta, Yohei Asano, et al.
Pageof 15